Abstract: The invention relates to a combination or panel of HIE-relevant protein and/or microRNA (miRNA) biomarkers that are released from injured tissues into biofluids such as blood in HIE, and their use as markers for detection of HIE. A selected panel of blood-based protein and/or miRNA HIE biomarkers that are measured at more than one time interval can aid in the diagnosis of HIE severity, and to determine the prognosis of poor versus good cognitive or overall patient outcome.

Abstract: This invention provides methods of detecting biomarkers in the biofluid of sepsis-associated encephalopathy (SAE) patients, including but not limited to glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase LI, Tan protein, Neurofilament light chain (NF-L), myelin basic protein (MBP), secretogranin, Copeptin, total all-spectrin, all-spectrin breakdown products (SBDP, including SBDP145, SBDP150, SBDP120 all-spectrin N-terminal fragment or SBDP150N), neuron specific enolase (NSE), mature brain derived neurotrophic factor (BDNF), and full-length Pro-BDNF. These biomarker peptides are markers of axonal and blood brain barrier integrity which can be used to diagnose SAE and to assess and predict cognitive performance and outcomes in acute presentations of sepsis.

Abstract: DNA aptamers that bind to tau protein at its phosphorylatable sites are identified. These disclosed DNA aptamers not only recognize tau at specific phosphorylatable sites, but also demonstrate inhibitory effects on phosphorylation and oligomer formation of tau protein. Molecular probes based on these disclosed DNA aptamers can be used as capture or detection agents to detect the levels of tau and phosphor-tau in cerebrospinal fluid as well as for cell-based or in vivo brain imaging in live animals or human. Compositions comprising these disclosed DNA aptamers can be used to arrest or treat the progression of tauopathy associated neurodegenerative disorders.

Abstract: DNA aptamers that bind to tau protein at its phosphorylatable sites are identified. These disclosed DNA aptamers not only recognize tau at specific phosphorylatable sites, but also demonstrate inhibitory effects on phosphorylation and oligomer formation of tau protein. Molecular probes based on these disclosed DNA aptamers can be used as capture or detection agents to detect the levels of tau and phosphor-tau in cerebrospinal fluid as well as for cell-based or in vivo brain imaging in live animals or human. Compositions comprising these disclosed DNA aptamers can be used to arrest or treat the progression of tauopathy associated neurodegenerative disorders.